Argos Therapeutics Obtains $42,500,000 New Round

  • Feed Type
  • Date
    8/26/2013
  • Company Name
    Argos Therapeutics
  • Mailing Address
    4233 Technology Drive Durham, NC 27704 USA
  • Company Description
    Argos Therapeutics (NASDAQ: ARGS) is developing breakthrough immunotherapies that target the unique features of a patient´s disease. This new generation of personalized cancer and infectious disease therapeutics, created using the Company´s “Arcelis” technology, trains the immune system to recognize and attack the disease.
  • Website
    http://www.argostherapeutics.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $42,500,000
  • Transaction Round
    Undisclosed
  • Proceeds Purposes
    The money will be used to fund a Phase 3 study – the final phase required by regulators before seeking approval to put a drug on the market – that was launched in January and ultimately is expected to include 450 patients.
  • M&A Terms
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor

Trending on Xconomy